Skip to content
Menu

Damora Therapeutics, Inc. DMRA

Full chart Compare
Set alert

Price alert · DMRA

All alert types
23.22 USD -1.08 (-4.44%)

Regular-session close

23.22 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

23.13 Day range 24.51
16.31 52-week range 34.14
YTD
+0.91%
1 year
+33.83%

5D +0.19 (+0.83%)

222324MonTueWedThuFri23.22
Market cap
1.44B
EPS (ttm)
1.71
Shares out
61.90M
P/E ratio
13.58
Forward P/E
-10.63
YTD return
+0.91%
1-year return
+33.83%
50-day average
21.79
200-day average
25.44
Enterprise value
1.11B
Volume
643.38K
Avg volume
576.73K
Open
23.81
Previous close
24.30
Day's range
23.13 – 24.51
52-week range
16.31 – 34.14
Beta
1.51
Analysts
Strong Buy
Price target
46.78 (+101.5%)
Earnings date
Mar 18, 2027

Key statistics

Price / book
3.93
Free cash flow
-18.55M
Total cash
528.48M
Total debt
1.10M
Return on equity
-115.80%
Short % of float
8.84%

Fundamental scorecard

5 of 25 checks passed on DMRA’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
DMRA Revenue — quarterly 0
DMRA Net income — quarterly -31.99M
DMRA EPS — quarterly -0.40

Earnings

DMRA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 18, 2027Dec 30, 2026-0.56041———
Nov 4, 2026Sep 30, 2026-0.48251-0.40+0.08+17.10%
Aug 11, 2026Jun 30, 2026-0.41395-0.39+0.02+5.79%
May 12, 2026Mar 31, 2026-0.21-0.62-0.41-195.24%
Mar 18, 2026Dec 31, 2025-0.14-3.24-3.10-2,216.35%
Nov 6, 2025Sep 30, 2025-0.09681-2.36-2.26-2,337.76%

Upgrades / downgrades

DMRA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026GuggenheimmainBuyBuy
Sep 29, 2026WedbushreitOutperformOutperform
Sep 25, 2026GuggenheimmainBuyBuy
Jul 30, 2026WedbushmainOutperformOutperform
Jul 27, 2026Jefferiesinit—Buy
Jul 21, 2026HC Wainwright & Co.reitBuyBuy

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
damoratx.com

News

Your note

Sign in to keep a note on DMRA — it syncs with the Stock Master app.

Insider holders

DMRA insider holders
InsiderRelationLatest transactionDateShares held
BRUNO JULIANNEDirectorConversion of Exercise of derivative securityFeb 8, 2026137,032
FAIRMOUNT FUNDS MANAGEMENT LLCDirector and Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 8, 20260
FIRMANI LORIChief Financial OfficerSaleJan 1, 2026931
HEWES LEMUEL BECKEROfficerStock Award(Grant)Jan 4, 2026264,629
JARRETT A JENNIFERChief Executive OfficerPurchaseSep 24, 2026512,500
SATTARZADEH SHERWINChief Operating OfficerStock Award(Grant)Jan 4, 2026190,376

Institution ownership

DMRA institution ownership
Holder% heldSharesValueReported
FMR, LLC15.43%9,549,056221.73MSep 29, 2026
Fairmount Funds Management LLC14.07%8,713,000202.32MSep 29, 2026
Avoro Capital Advisors LLC6.11%3,783,00087.84MSep 29, 2026
Venrock Adviser, LLC5.82%3,603,59583.68MSep 29, 2026
Blackrock Inc.5.68%3,514,57381.61MSep 29, 2026
RA Capital Management, L.P.3.88%2,399,70255.72MSep 29, 2026

Fund ownership

DMRA fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.96%1,835,05142.61MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.98%1,227,14528.49MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth Fund1.35%834,04019.37MAug 30, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.17%723,71916.80MSep 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.94%584,52913.57MAug 30, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund0.87%540,24612.54MSep 29, 2026